Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Roula Almufti
Observed name:
Roula Al‑Μufti
Institution:
King Faisal Specialist Hospital & Research Centre
Observed institutions:
King Saud bin Abdulaziz University for Health Sciences,
King Faisal Specialist Hospital & Research Centre,
King Abdulaziz Medical City,
King Abdullah International Medical Research Center,
National Guard Health Affairs
ORCID:
0009-0008-8188-3824
Observed ORCID:
0009-0008-8188-3824
OpenAlex ID:
A5014396599
The Outcomes of Diffuse Large B-cell Lymphoma Patients with Synchronous and Early Central Nervous System Involvement: A Single-Center Experience
2023
·
Mubarak Al-Mansour
, Saif Ahmed Saif
, et al.
·
Asian Pacific Journal of Cancer Prevention
·
6
PDF
Outcomes of high‑dose methotrexate for CNS prophylaxis in diffuse large B‑cell lymphoma with an intermediate or high CNS‑International Prognostic Index: A single‑center retrospective cohort study
2022
·
Mubarak Al‑Μansour
, Ahmed Absi
, et al.
·
Molecular and Clinical Oncology
·
6
PDF
Management of Early and Metastatic Breast Cancer: A Consensus Statement from Oncologists in Saudi Arabia
2025
·
Sabah Alaklabi
, Sadal Al Refaei
, et al.
·
Oncology and Therapy
·
1
PDF
Global disparities in the availability and reimbursement of systemic therapies for renal cell carcinoma: results of the International ARON-AID Survey
2026
·
Yuksel Urun
, Kannan Sridharan
, et al.
·
The Oncologist
PDF
Alectinib shows promise for the treatment of refractory ALK-positive large B-cell lymphoma: a case report
2026
·
Atheer Alsulami
, Roula Almufti
, et al.
·
Frontiers in Oncology
PDF
Evaluation of Efficacy and Safety of Nivolumab in Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma at King Abdulaziz Medical City-Jeddah/the Kingdom of Saudi Arabia Experience
2023
·
Amani Reda Alsafi
, Majed Alahmadi
, et al.
·
Blood
PDF
Show more works
View as search
Works count:
6
Citation count:
13
H-index:
2
I10-index:
Year
Topic
Type